GSK Investigational Site

Staten Island, New York 10314

1 studies enrolling now · 12 studies all time

What they study most

Alzheimer's Disease, Asthma, Diabetes Mellitus, Type 2, HIV Infection, Neoplasms, Prostate, Neuropathy, Diabetic, Schizophrenia

Studies at this site

• Open-label Extension Study in Participants With Early Alzheimer's Disease — Recruiting now
• Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease — Running, not enrolling
• Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus — Completed
• 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old — Completed
• ARI103094-Follow-Up Study for REDUCE Study Subjects — Completed
• A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment. — Completed
• A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide. — Completed
• Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia — Completed
• "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk — Completed
• Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin — Completed
• A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN) — Completed
• A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study) — Completed